---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-010895"
form_type: "8-K"
ticker: "RNXT"
cik: "0001574094"
company_name: "RenovoRx, Inc."
filed_at: "2025-05-15T23:59:59+00:00"
generated_at: "2026-05-21T04:58:07.961759+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# RenovoRx Q1 revenue ~$200K from RenovoCath sales; TIGeR-PaC trial 91 patients randomized

## Summary
- Q1 2025 revenue of ~$200K from commercial RenovoCath sales, exceeding internal expectations; gross profit $103K.
- Cash $14.6M as of Mar 31, 2025, up from $7.2M at Dec 31, 2024; funds commercial scale-up and trial completion.
- Phase III TIGeR-PaC trial: 91 patients randomized, 56 events (second interim analysis triggered); DMC review expected Q3 2025.
- Net loss $2.4M vs $1.1M in Q1 2024 due to higher operating costs and lower warrant liability gain.
- Management and Board purchased ~143K shares; new U.S. patent issued for TAMP platform (19 patents total).

## SEC filing metadata
- accession: 0001641172-25-010895
- form_type: 8-K
- ticker: RNXT
- cik: 0001574094
- company_name: RenovoRx, Inc.
- filed_at: 2025-05-15T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1574094/000164117225010895/0001641172-25-010895-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1574094/000164117225010895/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-010895
- JSON: https://secwatch.observer/filing/0001641172-25-010895.json
- Plain text: https://secwatch.observer/filing/0001641172-25-010895.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.